Clinical Trials Logo

Lymphoma clinical trials

View clinical trials related to Lymphoma.

Filter by:

NCT ID: NCT05208853 Not yet recruiting - Hodgkin Lymphoma Clinical Trials

An Exploratory Clinical Study Evaluating the Safety and Efficacy of Anti CD30 CAR T Cells in Patients With CD30+ Relapsed/Refractory Lymphoma

Start date: February 10, 2022
Phase: Early Phase 1
Study type: Interventional

This is a single-center, open label, single dose study of anti CD30 CAR-T cells injection in treatment of patients with relapsed/refractory CD30+ lymphoma.

NCT ID: NCT05186558 Not yet recruiting - Clinical trials for Lymphoma, Large B-Cell, Diffuse

Penpulimab Plus R2-GemOx Regimen in Relapsed or Refractory DLBCL

Start date: May 15, 2022
Phase: Phase 2
Study type: Interventional

This study evaluates the efficacy and safety of penpulimab plus lenalidomide, rituximab, gemcitabine and oxaliplatin (R2-GemOx) in patients with relapsed/refractory diffuse large B cell lymphoma (DLBCL). All patients will receive six cycles of penpulimab plus R2-GemOx. Afterwards, 1) patients who achieve complete response (CR)/unconfirmed (CRu)/partial response (PR) assessed by positron emission tomography/computedtomography (PET-CT) and are eligible for autologous stem cell transplantation (ASCT) will undergo ASCT. 2) Patients who achieve CR/CRu/PR assessed by PET-CT and are not eligible for ASCT will directly receive penpulimab and lenalidomide as maintenance treatment, penpulimab for a maximum of 6 months, lenalidomide monotherapy for 18 months. 3) Patients achieved stable disease (SD) or progression disease (PD) assessed by PET-CT will withdraw from this study and receive proper treatment based on investigator's decision.

NCT ID: NCT05179213 Not yet recruiting - Clinical trials for Angioimmunoblastic T-cell Lymphoma

Azacytidine Plus Chidamide in the Treatment of Relapsed and Refractory Angioimmunoblastic T-cell Lymphoma

Start date: January 1, 2022
Phase: Phase 2
Study type: Interventional

This is a multicenter prospective single arm phase II study. The purpose of this study is to evaluate the safety and efficiency of azacytidine combined with chidamide in the treatment of relapsed/refractory angioimmunoblastic T-cell lymphoma.

NCT ID: NCT05176275 Not yet recruiting - Lymphoma Clinical Trials

PET / CT Imaging and Safety in Patients With Lymphoma Treated With CD19 Car-t Cells

Start date: January 1, 2022
Phase: N/A
Study type: Interventional

The proliferation and distribution of CD19 CAR-T cells in lymphoma patients are investigated 68Ga-NOTA-RP25 by PET / CT imaging.

NCT ID: NCT05156554 Not yet recruiting - Lymphoma Clinical Trials

PEG-rhG-CSF Compared With rhG-CSF in Lymphoma Patients After Autologous Hematopoietic Stem Cell Transplantation

Start date: December 2021
Phase: N/A
Study type: Interventional

The purpose of the study is to evaluate the efficacy and safety of PEG-rhG-CSF compared with rhG-CSF on the recovery of hematopoietic function after autologous stem cell transplantation in patients with lymphoma.

NCT ID: NCT05155215 Not yet recruiting - Lymphoma Clinical Trials

Study to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) Mantle Cell Lymphoma

Start date: December 31, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

This is a phase I/II, open-label, multicenter study to assess the efficacy and safety of IM19 CAR-T cells in adult R/R Mantle Cell Lymphoma subjects

NCT ID: NCT05110950 Not yet recruiting - Lymphoma Clinical Trials

Endobronchial Ultrasound Needle Aspiration With and Without Suction

Start date: June 1, 2022
Phase: N/A
Study type: Interventional

The main purpose of the present study is to compare the diagnostic yield of different aspiration techniques in Ultrasound-guided Transbronchial Needle Aspiration (EBUS-TBNA) in the diagnosis of hilar/mediastinal adenopathy

NCT ID: NCT05106192 Not yet recruiting - Clinical trials for Non Hodgkin Lymphoma

Triamcinolone Acetonide Injections in Primary Cutaneous Lymphoma Plaques With a Novel Needle-free Drug-delivery System.

Start date: June 1, 2024
Phase: N/A
Study type: Interventional

A study to compare pain differences between using MedJet needle-free drug-delivery system with standard of care treatment for cutaneous T-cell lymphomas and cutaneous B-cell lymphomas in participants.

NCT ID: NCT05105412 Not yet recruiting - Clinical trials for Peripheral T-cell Lymphomas (PTCL)

Lenalidomide and Gemcitabine in Relapsed or Refractory Peripheral T-cell Lymphomas

Start date: October 31, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

This is a single country multi-center, open-label phase Ib/II single-arm study in relapsed or refractory PTCL patients. Patients will be treated with the combination of lenalidomide and gemcitabine until disease progression, intolerable toxicity, or patient withdrawal.

NCT ID: NCT05093140 Not yet recruiting - DLBCL Clinical Trials

Camrelizumab Plus R-CHOP Regimen in Untreated Primary Extranodal DLBCL

CREDIT
Start date: June 1, 2022
Phase: Phase 2
Study type: Interventional

To assess the efficacy and safety of camrelizumab combined with rituximab, vincristine, doxorubicin, cyclophosphamide and prednisone in the treatment of untreated primary extranodal DLBCL